Closing Stock Market SummaryThe S&P 500 eked out an intraday record high on Tuesday, but it closed lower by 0.1% in a lackluster session. The Nasdaq Composite (-0.1%), Dow Jones Industrial Average (-0.3%), and Russell 2000 (-0.3%) accompanied the benchmark index in negative territory with small declines.
Most sectors in the S&P 500 traded within their flat lines throughout the session amid no new macro catalysts, suggesting a bit of consolidation activity. The utilities (+0.5%), consumer discretionary (+0.3%), and consumer staples (+0.3%) sectors outperformed in positive territory. The information technology (-0.4%) and health care (-0.4%) sectors were influential laggards.
Despite little buying conviction, bullish investors cited the lack of meaningful profit-taking interest as a constructive development. The Philadelphia Semiconductor Index (-1.2%), however, did see late-day weakness following an FY24 guidance view shared by Applied Materials (AMAT 139.54, -3.51, -2.5%) at its Investor Day.
One supportive factor for risk sentiment was the decline in long-term interest rates. Demand for Treasuries might have been partially rooted in a view that economic growth rates could peak in the next few quarters. On a related note, the IMF raised its 2021 global economic growth forecast to 6% from 5.5%.
The 10-yr yield decreased six basis points to 1.66%. The 2-yr yield decreased one basis point to 0.16%. The U.S. Dollar Index decreased 0.3% to 92.30. WTI crude futures rebounded 1.1%, or $0.65, to $59.34/bbl after sliding 4% yesterday.
Shares of Illumina (ILMN 414.84, +30.30, +7.9%) rose 8% after the biotechnology company issued upside Q1 and FY21 revenue guidance due to an observation that its core business is exceptionally strong and growing ahead of expectations.
Separately, President Biden reportedly moved up the deadline for all adults to be eligible for a COVID-19 vaccine to April 19 from May 1. This was non-market moving news, unlike the first announcement of the May 1 deadline, presumably because nearly one-third of the U.S. population has already received one dose, according to data from the CDC.
Tuesday's economic data was limited to the JOLTs - Job Openings report, which showed job openings increase to 7.367 million in February from a revised 7.099 million in January (from 6.917 million). On Wednesday, investors will receive the Trade Balance for February, Consumer Credit for February, the FOMC Minutes from the March 16-17 meeting, and the weekly MBA Mortgage Applications Index.
- Russell 2000 +14.4% YTD
- Dow Jones Industrial Average +9.2% YTD
- S&P 500 +8.5% YTD
- Nasdaq Composite +6.3% YTD
After Hours Summary: FGEN -30% falls harply after clarification on roxadustat, but AKBA +10.2% up on the news; MAXN -7% falls on earnings/guidanceAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: SGH +0.6%
Companies trading higher in after hours in reaction to news: AKBA +10.2% (FGEN's news is seen as a positive for AKBA's competing anemia drug candidate), NVST +9% (to join S&P MidCap 400), IDCC +5.7% (to join S&P SmallCap 600), QGEN +4% (launches QIAseq DIRECT SARS-CoV-2 Kit), XTNT +3.9% (stock offering), NCLH +2.8% (US cruises could resume by mid-summer with restrictions, says CDC, according to Bloomberg), RCL +2.4% (US cruises could resume by mid-summer with restrictions, says CDC, according to Bloomberg), CCL +1.8% (US cruises could resume by mid-summer with restrictions, says CDC, according to Bloomberg), KXIN +1.6% (RENN announces $6 mln equity investment in KXIN), NUVA +0.5% (Simplify Disc receives approval from FDA for two-level cervical total disc replacement), AMZN +0.1% (Bezos says co is supportive of a rise in the corporate tax rate), ZEN +0.1% (names new Chief Marketing Officer), LLY +0.1% (LLY and INCY announce extension of review period for baricitinib sNDA), CXW +0.1% (files for mixed securities shelf offering)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: MAXN -7% (also announces major new initiative to expand in US solar market)
Companies trading lower in after hours in reaction to news: FGEN -30% (provides clarification of certain prior disclosures on roxadustat), FIXX -10.2% (stock offering), PHR -6.7% (stock offering), IONS -5.8% (announces private placement of $500 mln of convertible notes), LI -5% (convertible notes offering), OM -4.5% (stock offering), UPST -3.7% (stock offering), GNW -2.9% (decides to terminate merger agreement with China Oceanwide), RENN -1.6% (RENN announces $6 mln equity investment in KXIN), EVRI -1.4% (chairman retires), FOA -0.5% (new CFO), INCY -0.5% (LLY and INCY announce extension of review period for baricitinib sNDA), PCG -0.3% (issues statement disputing criminal charges related to 2019 Kincade Fire)
Gapping down
In reaction to earnings/guidance:
- BCEI -3.3%, GBX -3.3%, MRVI -1.6% (guides Q1 revs above consensus; also announces stock offering), PSXP -1.3%
Other news:
- ARES -7% (stock offering)
- TPTX -6.2% (reports clinical data from TPX-0046 study)
- UCTT -4.9% (commences $175 mln stock offering; also files for mixed securities shelf offering)
- NTST -3.3% (stock offering)
Analyst comments:
- ACAD -2.5% (downgraded to Neutral from Buy at Goldman; downgraded to Hold from Buy at Jefferies)
- YELP -1.4% (downgraded/resumed to In-line from Outperform at Evercore ISI)
- COOP -1% (downgraded to Mkt Perform from Outperform at Keefe Bruyette)
Gapping up
In reaction to earnings/guidance:
- ILMN +9.2% (guides Q1 and FY21 revs above consensus), SPNE +4.7% (guides Q1 and FY21 revs above consensus), LNN +1.7%, DCT +1.6%
Other news:
- SJ +38.2% (entered into a strategic alliance via a Master Services Agreement with Snipp Interactive)
- CARA +12.1% (to join S&P SmallCap 600)
- MUDS +7.3% (CNBC report that TOPPS will go public through a SPAC merger with MUDS)
- RMO +7.2% (Romeo Power and PACCAR (PCAR) enter long-term supply agreement for peterbilt 579 and 520 battery-electric vehicles)
- LABP +6.9% (receives FDA clearance for IND application for Omilancor)
- APTX +6.2% (recommences phase 2 study of NYX-458 in patients with cognitive impairment associated with parkinson's disease dementia and dementia with lewy bodies)
- TMDX +4.9% (shares halted as FDA is meeting today to review TransMedics' Organ Care System Heart System at 9 AM ET)
- MBRX +3.8% (engages IQVIA (IQV) to manage potential COVID-19 clinical trial)
- ROT +3.4% (Sarcos Robotics to merge with ROT)
- SEEL +3.3% (announces the signing of an agreement between Seelos and AptarGroup (ATR) for the co-exclusive use and supply of Aptar Pharma's Bidose Liquid System)
- BP +2.9% (reaches net debt target of $35 bln in Q1)
- DVAX +2.8% (Positive phase 1/2 results for Valneva's inactivated COVID-19 vaccine candidate using Dynavax's CpG 1018 adjuvant)
- SRRK +2.1% (announces positive 12-month top-line results from the TOPAZ Phase 2 clinical trial evaluating apitegromab in patients with type 2 and type 3 spinal muscular atrophy)
Analyst comments:
- SNAP +2.4% (upgraded to Overweight from Neutral at Atlantic Equities)
- VSH +2.1% (upgraded to Buy from Hold at Loop Capital)
- PARR +1.7% (upgraded to Buy from Neutral at Goldman)
- ALLE +1.6% (upgraded to Overweight from Underweight at Barclays)
Early premarket gappers
- Gapping up:
- CARA +11.8%, ILMN +9.3%, SPNE +4.7%, DCT +3.6%, NBR +3.2%, BP +2.8%, DVAX +2.6%, NVAX +1.6%, NIU +1.1%, JG +1%, LNN +0.9%, PRTA +0.8%, XOM +0.4%
- Gapping down:
- ARES -7.8%, UCTT -6.4%, TPTX -6.2%, BCEI -5.4%, NTST -3.4%, USAT -2.2%, ICAD -1.9%, MRVI -1.6%, KTOS -1.4%, GBX -0.8%